会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Pharmaceutical compounds
    • 药物化合物
    • US5338735A
    • 1994-08-16
    • US104272
    • 1993-08-12
    • John FairhurstDavid E. Tupper
    • John FairhurstDavid E. Tupper
    • A61K31/38A61K31/381A61P25/00A61P43/00C07D333/70C07D409/12C07D417/12
    • C07D409/12C07D333/70C07D417/12
    • Compounds of the formula: ##STR1## in which each R.sup.1 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or nitro, and n is 0, 1, 2 or 3, R.sup.2 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkenyl, R.sup.3 and R.sup.4 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl or C.sub.6-9 cycloalkyl optionally substituted by 1 to 4 C.sub.1-4 alkyl groups, R.sup.5 is optionally substituted phenyl, tetrahydronaphthyl, phthalimido, saccharinyl, glutaramido, C.sub.6-10 cycloalkyl optionally substituted with 1 to 4 C.sub.1-4 alkyl groups or a phenyl group, or C.sub.4-9 heterosubstituted cycloalkyl optionally substituted with 1 to 4 alkyl groups, x is 1, 2 or 3, y is 0 or 1 and z is 0, 1, 2 or 3; and salts thereof.The compounds are indicated for use in the treatment of disorders of the central nervous system.
    • 下式的化合物:其中每个R 1为氢,C 1-4烷基,C 1-4烷氧基,卤素或硝基,n为0,1,2或3,R 2为氢,C 1-4烷基或C 2 -4-烯基,R 3和R 4各自为氢,C 1-4烷基,任选取代的苯基或任选被1至4个C 1-4烷基取代的C 6-9环烷基,R 5为任选取代的苯基,四氢萘基,苯二甲酰亚氨基,糖精,戊二酰氨基, 任选被1至4个C 1-4烷基或苯基取代的C 6-10环烷基或任选被1至4个烷基取代的C 4-9杂取代环烷基,x为1,2或3,y为0或1,z为 是0,1,2或3; 及其盐。 化合物被指示用于治疗中枢神经系统疾病。
    • 6. 发明授权
    • 1H-2,1,3-benzothiadiazine-2,2-dioxide compounds or derivatives thereof
    • 1H-2,1,3-苯并噻二嗪-2,2-二氧化物化合物或其衍生物
    • US5929072A
    • 1999-07-27
    • US137788
    • 1998-08-21
    • John Fairhurst
    • John Fairhurst
    • A61K31/54A61P25/00C07D285/16C07D417/14C07D513/04C07D279/00
    • C07D285/16A61K9/2059A61K9/4866C07D417/14C07D513/04
    • A pharmaceutical compound having the formula: ##STR1## in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3,R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-4 alkyl,R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkyl, or R.sup.3 and R.sup.4 together form an alkylene link of formula --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 --, or R.sup.4 and R.sup.5 together with the carbon atom to which they are attached form a C.sub.3-6 cycloalkyl group,R.sup.6 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino,the dotted line represents an optional double bond, andthe fluorine atom is attached at the 6 or 7-position;and salts and esters thereof.
    • 一种具有下式的药物化合物:其中n为1或2,m为1或2,p为1至6,q为0或1至3,R1和R2各自为氢或C1-4烷基,R3,R4 和R 5各自为氢,C 1-4烷基,任选取代的苯基或任选取代的苯基-C 1-4烷基,或者R 3和R 4一起形成式 - (CH 2)3 - 或 - (CH 2)4 - 的亚烷基连接,或 R4和R5与它们所连接的碳原子一起形成C 3-6环烷基,R 6是C 1-4烷基,C 1-4烷氧基,羧基,羟基,氰基,卤素,三氟甲基,硝基或氨基,虚线 表示任选的双键,氟原子连接在6位或7位; 及其盐和酯。